Modulation of mineralocorticoid receptor (MR) signalling with AZD9977 for the treatment of diabetic cardiac myopathies (#123)
Monica Kanki
1
2
,
Elliott Vivekanatham
1
3
,
Gregory Tesch
3
,
Timothy Cole
4
,
Peter Fuller
5
,
Daniel Donner
6
,
Helen Kiriazis
6
,
Krister Bamberg
7
,
Morag Young
1
8
- Cardiovascular Endocrinology Laboratory, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia
- Department of Medicine (Alfred Health), Monash University, Clayton, Victoria, Australia
- Department of Physiology, Monash University, Clayton, Victoria, Australia
- Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
- Centre of Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia
- Experimental cardiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
- Early Clinical Development, Research and Early Development, BioPharmaceuticals R&D AstraZeneca, Gothenburg, Sweden
- Department of Cardiometabolic Health, University of Melbourne, Melbourne, Victoria, Australia